This MedLibrary.org supplementary page on Alosetron is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Alosetron
|
|
| Systematic (IUPAC) name | |
| 5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]- 3,4-dihydro-2H-pyrido[4,3-bindol-1(5H)-one |
|
| Identifiers | |
| CAS number | |
| ATC code | A03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H18N4O |
| Mol. mass | 294.351 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 50–60% |
| Protein binding | 82% |
| Metabolism | Hepatic (including CYP2C9, CYP3A4 and CYP1A2) |
| Half life | 1.5–1.7 hours |
| Excretion | Renal 73%, faecal 24% |
| Therapeutic considerations | |
| Pregnancy cat. |
B (U.S.) |
| Legal status |
℞-only (U.S.) |
| Routes | Oral |
Alosetron is a 5-HT3 antagonist used for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women only. It was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted; it was the first drug ever returned to the U.S. market after withdrawal for safety concerns.[1] It is currently marketed by GlaxoSmithKline under the trade name Lotronex.
Contents |
Mode of action
Alosetron, while being a 5-HT3 antagonist like ondansetron, is not an antiemetic. Alosetron has an antagonist action on the 5-HT3 receptors of the enteric nervous system of the gastrointestinal tract.
Serious adverse effects
Alosetron was withdrawn in 2000 following the association of alosetron with serious life-threatening gastrointestinal adverse effects. The cumulative incidence of ischaemic colitis was 2 in 1000, while serious complications arising from constipation (obstruction, perforation, impaction, toxic megacolon, secondary colonic ischaemia, death) was 1 in 1000.[2]
References
- ^ Pollack, A. "F.D.A. Panel Recommends M.S. Drug Despite Lethal Risk", The New York Times, 2006-03-09. Retrieved on 2008-03-13.
- ^ GlaxoSmithKline plc. Lotronex (U.S. Prescribing Information). Brentford: GlaxoSmithKline; 2002.
See also
|
|||||||||||
Wikipedia content modification information:
- This page was last modified on 12 June 2008, at 22:36.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Alosetron".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.